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Abstract
A component to the problem of inducing broad neutralizing HIV-1 gp41 membrane proximal external region (MPER)
antibodies is the need to focus the antibody response to the transiently exposed MPER pre-hairpin intermediate
neutralization epitope. Here we describe a HIV-1 envelope (Env) gp140 oligomer prime followed by MPER peptide-
liposomes boost strategy for eliciting serum antibody responses in rhesus macaques that bind to a gp41 fusion
intermediate protein. This Env-liposome immunization strategy induced antibodies to the 2F5 neutralizing epitope
664DKW
residues, and these antibodies preferentially bound to a gp41 fusion intermediate construct as well as to MPER scaffolds
stabilized in the 2F5-bound conformation. However, no serum lipid binding activity was observed nor was serum
neutralizing activity for HIV-1 pseudoviruses present. Nonetheless, the Env-liposome prime-boost immunization strategy
induced antibodies that recognized a gp41 fusion intermediate protein and was successful in focusing the antibody
response to the desired epitope.
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Introduction
The membrane proximal external region (MPER) of HIV-1
gp41 contains the epitopes of broadly neutralizing antibodies 2F5
and 4E10 [1,2,3,4] that are important targets for HIV-1 vaccine
design. The MPER of gp41 is a highly conserved region, rich in
aromatic residues, and its role in HIV-1 fusion is evident from
studies showing that mutation of tryptophan residues in the MPER
inhibits cell fusion and viral infectivity [5,6]. Passively adminis-
tered neutralizing antibodies 2F5 and 4E10 can protect against
vaginal SHIV transmission [7] indicating that if induced in high
titers, such broadly neutralizing antibodies could be effective
against HIV-1 infection. However, MPER-specific broadly
neutralizing antibodies are rarely made in HIV-1 infection [8,9]
or following HIV-1 envelope protein (Env) vaccination
[10,11,12,13]. Structural constraints that include transient expo-
sure of neutralizing epitopes [14,15], as well as immunological
tolerance mechanisms [16] are explanations for inability to
routinely induce 2F5 or 4E10-like antibody responses. Thus,
there are two barriers to induction of MPER broad neutralizing
antibodies that must be overcome; the transient exposure and poor
immunogenicity of subdominant MPER neutralizing epitopes, and
tolerance control of the B cells capable of responding to the MPER
neutralizing epitopes [16,17].
The high affinity binding of 2F5 and 4E10 mAbs to the
membrane-displayed MPER followed a two-step encounter-
docking model that was distinct from the binding pattern observed
in MPER antibody interaction with gp41 epitopes in the absence
of lipids [18,19]. These and other data suggest that MPER
residues are orientated or presented differently on a lipid bi-layer
compared to free peptides [15,19,20,21]. The lack of binding of a
non-neutralizing MPER mAb 13H11, the binding site of which
overlaps that of 2F5, to MPER peptide-liposomes [18], further
highlights the differences in configuration of the MPER residues in
peptide-lipid complexes when compared to MPER peptide in
solution. In contrast, gp41 peptides exist in multiple conformations
- unstructured, a-helical, or b-turn [22,23,24] and MPER peptides
alone as immunogens generally are ineffective for the induction of
neutralizing antibodies (reviewed in [25]). MPER peptides in
micelles or in liposomes with membrane anchor tags are likely to
be less flexible and more likely to adopt a relatively ordered
conformation [19,20,21,26]. Ofek et al., recently showed that
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target the 2F5-bound peptide conformation [27]. However, to
date, no studies have demonstrated induction of gp41 fusion
intermediate antibodies by Env or peptide immunogens.
In this study we report that a prime-boost regimen of oligomeric
gp140 protein and MPER peptide-liposomes was required to
induce MPER binding serum responses specific for the 2F5 core
gp41 epitope
664DKW amino acids in both guinea pigs and rhesus
macaques. The induced antibodies in Rhesus macaques bound the
DKW sequence of the nominal 2F5 epitope, and to a protein
construct designed to mimic a gp41 fusion intermediate confor-
mation.
Results
Immunogenicity of gp140 oligomer protein and MPER
peptide liposomes immunogens in guinea pigs
Broadly neutralizing gp41 MPER mAbs 2F5 and 4E10 either
do not bind or bind poorly to many Env gp140 oligomers
[14,18]. We have previously reported that MPER epitopes are
indeed exposed in JRFL gp140CF Env protein allowing binding
of 2F5 and 4E10 mAbs [18]. We, therefore, first immunized
guinea pigs to determine if either JRFL gp140CF or MPER
peptide-liposome complexes that both bind 2F5 and 4E10 mAbs
could induce antibody responses to the MPER neutralizing
epitope
664DKW.
Immunization of JRFL gp140CF oligomer protein alone (36)
induced low levels of weak avidity MPER specific responses as
indicated by the 100-fold faster dissociation rate (kd) when
compared to that of 2F5 mAb (Figure 1A&C). On the other
hand, MPER peptide-liposome complexes immunized alone in
guinea pigs induced relatively higher avidity antibodies as judged
by relatively slower dissociation rates (,6-fold faster in comparison
to that of 2F5 mAb) (Figure 1B&D). Thus, compared to Env JRFL
gp140CF protein, MPER peptide liposomes induced higher
avidity 2F5 peptide-specific responses.
Next we determined the fine specificity of MPER specific
responses induced by these two immunogens alone. Only guinea
pig 1402 when immunized with JRFL gp140CF gave sufficiently
high MPER responses. In serum from animal 1402, JRFL
gp140CF immunization induced responses targeting
666W residue
and an additional residue (
669L) outside the 2F5 core (Figure 1E)
that is a critical residue for a non-neutralizing MPER mAb [28].
The MPER peptide-liposome immunizations induced responses
targeting residues
664D in two animals (1702 and 1703),
665Ki n
one animal (1704) and both
664D and
665K in one animal (1705,
Figure 1E). Thus, neither JRFL gp140CF nor MPER peptide-
liposomes elicited responses with specificity focused entirely on the
Figure 1. Comparison of gp41 MPER specific antibody responses induced in guinea pigs by JRFL gp140CF and MPER peptide-
liposomes. The immunization scheme of the study is shown in the top panel. A–B: The 2F5 epitope peptide (SP62 peptide) specific responses in
guinea pigs sera (at 1:50 dilution) determined by SPR are shown after vaccination with JRFL gp140CF (A) and MPER peptide-liposome (B). PB, pre-
bleed; P1–P3, post-immune bleeds 1–3. C–D: SPR sensogram displaying the comparison of 2F5 epitope peptide specific binding of guinea pig 1402
(C) and 1703 (D) sera at different time points with 2F5 mAb is shown as representative data. The estimated dissociation rates (kd) from the sensogram
are indicated for 2F5 mAb and Post-bleed 3 (P3). E: Epitope mapping of post-immune bleed 3 of guinea pigs 1402 (immunized with JRFL gp140CF
alone) and 1702–1705 (immunized with MPER656 peptide-liposomes alone) is shown in comparison to 2F5 mAb. The normalized binding shown is
the ratio between binding responses of sera to the alanine scanning mutant peptides and WT 2F5 epitope peptide SP62. Alanine substitution of
residues that resulted in $50% reduction in binding are indicated adjacent to the symbols. Data is representative of at least two measurements on
adjacent spots on the same sensor chip.
doi:10.1371/journal.pone.0027824.g001
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664DKW residues that are critically involved in
mAb 2F5 neutralization.
Since we observed weak 2F5 epitope specific responses with
JRFL gp140CF alone and only partial focusing on the 2F5 core
epitope with MPER peptide liposomes, we next asked whether a
heterologous prime-boost regimen using both immunogens
would induce antibody responses with specificity restricted to
t h ec o r et r i p e p t i d e
664DKW residues. To determine the optimal
prime-boost regimen, we used two different strategies. First, we
tested a MPER peptide-liposome prime-JRFL gp140CF boost
regimen as shown in Figure 2A (same animals in Figure 1B were
boosted). In the second strategy, we used a single JRFL gp140CF
prime followed by MPER liposome boost (36)a ss h o w ni n
Figure 2D. The MPER peptide-liposome prime-JRFL gp140CF
boost regimen resulted in immune responses (Figure 2B) that
targeted either
664Do r
665K (Figure 2C) and were not different
from the results obtained with MPER peptide-liposome alone
immunizations. In contrast, as shown in Figures 2D–F, a single
prime with JRFL gp140CF followed by MPER peptide-
liposomes elicited 2F5 peptide specific responses (Figure 2E)
that targeted two of the tripeptide core residues,
664Da n d
665K,
in all three animals (Figure 2F). Thus, the strategy of priming
once with JRFL gp140CF and boosting (36)w i t hM P E R
peptide-liposomes induced antibody specificity that was closer to
that of the neutralizing antibody 2F5. In a separate study, the
induction of 2F5-like specificity was reproducible and in one
animal two rounds of prime-boost immunizations progressively
focused the response to the 2F5 core tripeptide
664DKW residues
(Figure S9).
Non-human Primate (NHP) serum antibody responses to
JRFL gp140CF and MPER peptide-liposomes
To determine if the strategy of gp140 prime/MPER peptide-
liposome complex boost for induction of anti-
664DKW antibodies
would translate to non-human primates, we next examined the
immunogenicity of JRFL gp140CF alone and MPER peptide-
liposomes alone in rhesus macaques. Immunization of JRFL
gp140CF oligomer alone induced weak (,1:100 titer) MPER-
specific responses in rhesus macaques (Figure 3A) although end-
point antibody titers against the JRFL gp140CF Env protein were
$1/10,000 (Figure S1). In contrast, MPER peptide-liposome
complexes alone did induce MPER-specific antibodies
(Figure 3B), but the specificity of the MPER liposome-induced
responses was restricted to residue
664D, with weak and
Figure 2. MPER specific immunogenicity and fine specificity of different prime-boost regimens in guinea pigs. A–C: Immunization
scheme (A), 2F5 epitope peptide (SP62 peptide) specific binding serum responses (B) and fine specificity of post immune bleed 7 (C) are shown for
MPER656 liposome prime-JRFL gp140CF boost regimen are shown. PB, pre-bleed; P1–P7, post-immune bleeds 1–7. D–F: The JRFL gp140CF prime-
MPER656 liposome boost regimen scheme (D), 2F5 epitope peptide specific binding serum responses J and the fine specificity of post immune
bleed 4 (F) are shown. Data is representative of at least two measurements on adjacent spots on the same sensor chip.
doi:10.1371/journal.pone.0027824.g002
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665K of the 2F5 core tripeptide
664DKW (Figure 3C–E). Thus, antibody responses with the
desired amino acid targeting (
664DKW) were not achieved in
rhesus macaques immunized with MPER peptide-liposomes or
JRFL gp140CF oligomer alone.
Rhesus macaque antibody responses to heterologous
prime-boost immunization
Since we observed that heterologous prime-boost immuniza-
tions in guinea pigs were more effective in inducing
664DKW -
specific antibody responses, we next tested whether the JRFL
gp140CF prime-MPER peptide-liposome boost regimen would
also focus the induced antibody responses on the gp41
664DKW
neutralizing epitope in rhesus macaques. The Env prime, MPER-
liposome boost immunization regimen used in rhesus macaques is
shown in Figure 4A (same animals in 3A were boosted). The
MPER specific responses in sera from four immunized animals at
different points are shown in Figures 4B–C. MPER specific
responses began to appear in sera collected 3 weeks after first
MPER peptide-liposome complex boost (week 51). Each
subsequent boosting enhanced the level of 2F5 peptide binding
responses, with two animals having about 3-fold higher binding
responses than the remaining two (Figure 4B–C). The responses
declined during the interval between the 2
nd and 3
rd boost but
then increased again following the 3
rd MPER peptide-liposome
complex boost (Figure 4B–C). Serum antibody binding dissoci-
ation rates, a measure of binding avidity, was stable over time
(Figure 4D).
Fine specificity mapping of induced antibody demonstrated
that the MPER-specific responses elicited after the first boost of
MPER liposomes were targeted to one or two core
664DKW
residues and as well targeted additional MPER residues (L669,
W670), outside the 2F5 core but within the MPER hinge region
(Figure 5). However, following the second and third MPER
peptide-liposome complex boosts, rhesus monkey serum
antibody responses to
664DKW residues were consistently
induced (Figures 5A–D). In 3 out of 4 animals (03525, 41546
and 51902), sera collected one week after the third boost (week
56) showed MPER specific responses in which all three
664DKW residues were recognized by serum antibodies
(Figures 5A,B and D). In the fourth animal (51834), the
specificity for all three DKW residues was also observed in
week 55 bleed but with weaker and transient involvement with
W
666 in week 56 (Figure 5C). Thus, these results indicated that
using a heterologous prime-boost regimen of JRFL gp140CF/
MPER peptide-liposome complexes, MPER-specific antibody
responses in rhesus macaquesc o u l db ef o c u s e dt oM P E R
664DKW amino acids.
Figure 3. Comparison of MPER specific immunogenicity of different immunogens in rhesus macaques. The immunization scheme is
shown at the top. A–B: MPER specific binding responses of sera from immunized rhesus macaques at different time points are shown for (A) JRFL
gp140CF (ASO1B adjuvant) and (B) MPER peptide liposome immunogens (in emulsigen+oCpG). C–E: The fine specificities of MPER specific responses
elicited by MPER liposomes in rhesus macaques are shown for post immunizations 2–5 sera. F: The alanine substituted peptides used in epitope
mapping of MPER responses. The dotted ellipses in C, D and E highlight the predominance of
664D specific MPER responses. Data is representative of
at least two measurements on adjacent spots on the same sensor chip.
doi:10.1371/journal.pone.0027824.g003
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protein by Env gp140 prime, MPER liposome boost
regimen
While induction of pre-hairpin intermediate antibodies is
difficult, induction of post-fusion six-helix bundle antibodies is
common [17,29,30,31]. The neutralizing MPER antibodies 2F5
and 4E10 target the fully extended fusion intermediate state of
HIV-1 gp41 [14,32] whereas non-neutralizing MPER antibody
13H11 recognizes a helical MPER structure that is consistent with
HIV-1 gp41 in a post-fusion six-helix bundle conformation [28].
To fully understand the gp41 conformation targeted by the
induced antibodies, we tested three different recombinant gp41
proteins; the gp41MN protein, and two gp41-inter constructs-
gp41-inter and GCN4 gp41-inter [14,32]. While both trimeric
gp41 inter proteins present the MPER in its putative fusion
intermediate conformation, gp41-inter construct has an additional
six-helix bundle attached at its N-terminus end [14,32]. Thus
antibodies that exclusively recognize the fusion intermediate
conformation of gp41 will bind to both the gp41 inter proteins,
while those that do not target the fusion intermediate will bind to
gp41 and/or gp41-inter but not GCN4-inter [32]. JRFL gp140CF
immunized macaques sera (week 14, Figure S2), which gave no
MPER peptide binding, bound to both gp41 MN and gp41-inter
but not to GCN4 gp41-inter. The gp41 specific antibodies induced
by JRFL gp140CF, therefore, are unable to recognize the fusion
intermediate conformation of gp41. Similarly, the week 48 sera
(following priming with JRFL gp140CF protein), which showed no
detectable MPER specific responses by SPR, also gave no binding
to GCN4-gp41 inter (Figure 6B–E). Remarkably the post-
MPER656 liposome boost sera (Weeks 52–56) that gave DKW-
specific responses bound strongly to GCN4-gp41 inter (Figure 6B–
E). Since GCN4-gp41 inter is recognized by 2F5 and not by
13H11 (Figure 6A), the GCN4-gp41 inter binding of MPER
specific responses in these rhesus macaques sera indicated that the
induced DKW-specific antibodies were capable of recognizing the
fusion-intermediate state of gp41. Furthermore, as shown in
Figure 7, the purified IgG binding responses gave higher binding
to both gp41-inter and GCN4-inter while the binding to gp41 MN
was much lower. These results indicated that MPER peptide-
liposomes boost can focus the antibody responses to the 2F5 core
DKW residues and induce antibodies in rhesus macaques that
preferentially bound the MPER conformation in the fusion-
intermediate protein. Thus, the JRFL gp140CF/MPER peptide-
liposome complex regimen has solved one component of the
problem for induction of neutralizing anti-gp41 MPER antibodies,
i.e., induction of antibodies with specificity for a fusion-
intermediate conformation of gp41 MPER.
JRFL gp140CF prime, MPER liposome boost regimen
induced antibodies bind to 2F5-epitope scaffold proteins
We next asked whether the JRFL gp140CF prime:MPER656
liposome boost regimen induced antibodies recognize the 2F5
epitope in the 2F5-bound conformational state. Ofek et al recently
demonstrated that computationally designed 2F5-epitope scaffolds
Figure 4. MPER specific binding responses of Rhesus macaques sera in gp140 prime-MPER liposome boost regimen. A: The
immunization scheme involving JRFL gp140CF prime (ASO1B adjuvant) and MPER656/MPL-A/R848 (emulsigen+oCpG) liposome boost regimen is
shown. The arrows indicate the weeks at which immunization was done. B: ELISA end point titer of the 2F5 epitope peptide specific responses in
rhesus macaques sera at different time points. C: The 2F5 epitope peptide specific binding of monkeys sera determined by SPR is shown post
vaccination at different time points. D: Representative data of SPR sensogram of rhesus macaque #41546 sera at different time points binding to 2F5
epitope peptide as compared to 2F5 mAb (10 mg/ml) is shown. The estimated dissociation rates (kd) are indicated for samples at week 51 and 56 as
well as for the control 2F5 mAb. Data is representative of at least two measurements on adjacent spots on the same sensor chip.
doi:10.1371/journal.pone.0027824.g004
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nanomolar affinity for 2F5 mAb with varying degrees of binding
entropy [27]. Crystal structure analysis of one of the scaffold (ES2)
which had the highest affinity towards 2F5 and the most
entropically favorable interaction with 2F5 showed that the epitope
conformation mimicked that of the 2F5-bound conformation [27].
Thus, we examined the binding of pre- (week 48) and post-
MPER656 liposome (weeks 52–56) immune serum IgG of rhesus
macaques to 2F5-epitope scaffoldsES2,ES4andES5.Aspreviously
reported [27], 2F5 mAb and 11F10, a mouse monoclonal antibody
elicited in a ES5–ES1 prime:boost immunization regimen bound
strongly to the ES proteins (8A–C). The non-neutralizing 13H11,
which recognizes the 2F5 epitope core (
664DKW) and L669 [15] in
a helical conformation [28] did not bind the 2F5-epitope scaffolds
(Figure 8A–C). Interestingly, the post-MPER656 liposome immune
serum IgG of rhesus macaques bound to 2F5-epitope scaffolds ES2,
ES4 and ES5 (Figure 8D–F). As also observed with GCN4-gp41-
interbinding,thepostJRFLgp140induced antibodies(week48)did
not bind to any of the scaffolds (Figure 8D–F).
To determine if the ES2 scaffold shares antigenicity with the
gp41 inter proteins, we determined the ability of the 11F10 mAb
to bind to gp41-inter proteins. We found that 11F10 bound to
gp41 inter proteins (Kd=7.9 and 7.8 nM to GCN4-gp41 inter and
92Ug gp41-inter respectively), but not to the gp41 MN protein
(Figure S3). 11F10 mAb, therefore, selectively binds to the putative
fusion-intermediate conformation of gp41. However, unlike 2F5
mAb 11F10 did not bind anionic lipids (Figure S4) nor neutralized
HIV-1 [33]. Thus, these data indicate that the
664DKW specific
antibodies elicited in rhesus macaques can not only recognize
fusion-intermediate protein but can also bind to 2F5-bound
conformation of gp41 MPER.
Neutralization capacity of rhesus monkey serum
antibodies that bind to gp41 fusion-intermediate protein
Having elicited
664DKW-specific antibodies that recognize the
gp41 fusion-intermediate conformation and 2F5-bound confor-
mation in rhesus macaques, we asked whether these responses
would neutralize HIV-1. In TZM/bl pseudovirus assays (Table-1)
Figure 5. Mapping of critical residues involved in MPER specific Rhesus macaques serum responses. Normalized binding responses of
immune sera from rhesus macaques primed with JRFL gp140CF and boosted with MPER656 liposomes. Panels A–D are for animals 03525, 41546,
51384 and 51902. The dotted circle highlights the mapping of MPER specific responses to D
664KW residues as did 2F5 mAb. Data is representative of
at least two measurements on adjacent spots on the same sensor chip.
doi:10.1371/journal.pone.0027824.g005
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taken at week 56 when the
664DKW core antibody responses were
observed.
The lipid reactivity of 2F5 and 4E10 through the hydrophobic
residues in the CDR H3 loop is critical for HIV-1 neutralization
but not for antigen binding [29]. Thus, we asked whether the
GCN4-gp41 inter binding
664DKW-specific antibodies elicited in
rhesus macaques had any lipid reactivity. Purified IgG from rhesus
macaque sera at weeks 0, 48, 52, and 55 was tested for reactivity to
liposomes containing cardiolipin, or phosphatidylserine (PS) that
do bind to mAb 2F5 [34]. There was no specific binding of rhesus
macaque IgG purified from either the pre- or the post-vaccination
sera to either cardiolipin (Figure S5) or PS (not shown). Taken
together these results suggested that the induced DKW-specific
rhesus macaque antibodies lacked the ability to bind lipids, and
were therefore, unable to neutralize HIV-1.
Discussion
In this study, we report that the membrane bound form of gp41
MPER peptides can present epitopes in a conformation that
induce antibodies that not only target the core
664DKW epitope of
the neutralizing antibody 2F5, but also recognize a fusion-
intermediate construct of HIV-1 gp41 MPER as well as the 2F5
bound MPER conformation. The induction of antibodies with
specificity for 2F5 tripeptide core residues was acquired only after
priming with an oligomeric gp140, followed by multiple boosts
with MPER liposomes, implying that successive boosting was
critical for the expansion and maturation of B cells with receptors
that target the core
664DKW MPER epitope. Although the
induced responses were not neutralizing, the success of this
immunization strategy to induce a putative fusion intermediate/
2F5 bound conformation recognizing antibodies provides a
solution to one barrier to inducing gp41 neutralizing antibodies.
One explanation for the failure of earlier vaccines is that the
immunogens used were not configured in the conformation
needed to elicit a gp41 fusion-intermediate antibody response.
Our current regimen overcomes this problem. However, during
HIV-1-induced CD4 T cell fusion, the MPER is only exposed
transiently [14]. In order to capture such a transient epitope we
have hypothesized that elicited antibodies should be capable of
concentrating on virion surfaces by weak interactions with viral
membrane lipids [29]. We have also hypothesized that such
antibodies might not be easily made since lipid or protein
autoreactivity of MPER specific antibodies may evoke tolerance
controls [34]. Indeed, this has been shown to be the case in 2F5
Figure 6. The MPER specific serum responses in rhesus macaques recognize the mimic of fusion-intermediate gp41 structure. A:
Comparison of binding of 2F5 and 13H11 Fabs to GCN4-gp41-inter, a mimic of pre-hairpin intermediate structure of gp41. B–E: SPR sensogram of
rhesus macaques sera (1:50 diluted) binding to GCN4-gp41-inter. Each panel in B thru E compares the binding of sera obtained prior to MPER656
liposomes boost (week 48) and post-MPER656 liposomes boost (weeks 52–56). Data is representative of two measurements.
doi:10.1371/journal.pone.0027824.g006
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(Verkoczy L and Haynes B, unpublished).
Several earlier studies have used specialized structures to
present the MPER sequences in the immunogens. Arnold et al
had used recombinant human rhinoviruses displaying ELDKWA
epitope flanked by residues promoting b- turn [35], Zhang et al
expressed chimeric virus like particles presenting a bovine
papillomavirus L1-HIV-1 gp41 fusion protein [36] and Liang
et al had grafted ELDKWA into variable loops in HIV-1 gp120
[37]. These and other studies have reported induction of
antibodies that target the 2F5-nominal epitope but with minimal
or no neutralization [24,35,36,37,38,39,40]. Although in these
studies, induced antibody responses were targeted to the
ELDKWA sequence, fine specificity mapping data are not
available for determination if the antibody responses were
restricted to the core tripeptide
664DKW. Similarly, in studies
with immunogens with 4E10 epitope, the lack of fine specificity
data does not allow assessment of the epitopes induced by the
immunogens [13,41]. More recently, however, MPER directed
neutralizing antibodies were reported to be elicited using
immunogens consisting of gp41 six helix bundle and an exposed
MPER tail with double mutation [42] and a chimeric construct in
which the HIV gp120 was replaced with HA1 subunit of influenza
virus [43]. That weak MPER neutralizing activity can sporadically
be induced and detected is not surprising, since a subset of
chronically HIV-1 infected subjects have been reported to make
neutralizing antibodies that bind within the MPER [9,44,45].
However, high and sustained levels of MPER antibodies are not
induced in the setting of vaccination and this may relate to
immunoregulatory control of poly reactive MPER antibodies with
more potent neutralizing activity such as 2F5 and 4E10 [16,46].
Guenaga et al. [33] and Ofek and colleagues [27] recently
demonstrated that a heterologous scaffold prime-boosting strategy
induced antibody responses to the engrafted 2F5 epitopes, and
that these antibodies bound to the MPER peptide that existed in
the 2F5 bound conformation. These latter studies did not
determine reactivity with gp41 fusion-intermediate forms, nor
did these scaffold-induced antibodies neutralize HIV-1. However,
like the MPER liposomes induced antibodies described in this
study, one antibody, 11F10, isolated from the above 2F5 scaffold
murine immunization study [27] also bound preferentially to the
gp41-inter conformation and not to the recombinant gp41 MN
(Figure S3). In this study we have described the induction of
antibodies that preferentially bind to a gp41 fusion- intermediate
Figure 7. Comparison of JRFL gp140CF primed and MPER656 liposomes boosted rhesus macaque serum IgG binding to different
conformational states of gp41. A–D: SPR sensogram of rhesus macaques serum IgG (100 mg/ml) binding to GCN4-gp41 inter (solid lines), gp41-
inter (dotted lines) and recombinant gp41 (broken lines). The IgGs purified from Week 56 (for animals 03525 and 51902), Week 52 (animal 41546) and
Week 52 (animal 51834) sera were used. Data is representative of two measurements.
doi:10.1371/journal.pone.0027824.g007
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binding to 2F5-epitope that is pre-configured in the 2F5 antibody
bound state. Thus both immunization strategies, that of Ofek et al.
(30) and the present study, have elicited antibodies that recognize
the putative fusion-intermediate gp41 conformation. This is
underscored by the fact the epitope scaffold induced antibody
11F10, which recognizes the 2F5 bound conformation of gp41,
can also recognize the putative gp41 fusion-intermediate confor-
mation as presented in the constrained gp41-inter protein.
It is notable in the studies of Ofek et al [27] and Guenaga and
colleagues [33] that 2F5 scaffolds that were more flexible were
better immunogens than those that were rigid. Thus immunogens
that allow antigen recognition with induced fit may allow better
adaptability to the available naı ¨ve B cell repertoire. Our studies
using a heterologous prime boost and with MPER presented on
liposomes provide an alternative strategy to inducing antibodies
with specificity for the 2F5 core epitope, and in all likelihood
allowed induced fit binding of 2F5 core epitope-specific antibodies.
Importantly, the antibodies induced by our heterologous prime
and boost preferentially bound gp41 fusion- intermediate
constructs versus the recombinant gp41 MN. Thus, we have
demonstrated that in addition to 2F5 stabilized structures
engrafted on acceptor proteins, MPER liposomes when used as
a boost can induce gp41-inter protein specific antibodies.
It is tempting to speculate that the MPER presentation in JRFL
gp140CF is capable of priming for
664DKW responses but this
response remains subdominant in the presence of other immuno-
dominant gp140 epitopes. We have shown that JRFL gp140CF
primarily induces antibody responses that target the recombinant
gp41 MN and not the GCN4-gp41 inter protein (Figure S2). We
postulate that B cells to the MPER
664DKW were primed by JRFL
gp140 and then were expanded when boosted with MPER
peptide-liposome complexes lacking other immunodominant
epitopes. Although the 2F5 epitope portion of MPER sequence
of the priming Env gp140 does not differ (Figure S6) from that
used in the MPER liposomes (boost immunogen), the gp140
MPER likely presents a different structure than those on the
MPER peptide liposomes. This is evident in the differences in
binding affinities of 2F5 or 4E10 to JRFL gp140CF and MPER
liposomes [18,19] and in the nature of the induced antibodies
(Figure 7 and S2). The heterologous prime/boost strategy with the
two MPER structures have thus likely led to the focusing of the
antibody responses to the 2F5 core residues and thus resulted in
the induction of gp41 inter specific antibodies. Additionally,
incorporation of TLR 4 and 7/8 agonists in the MPER peptide-
liposome complexes also may have played a role in enhancing
immune responses in the boosting stage. In this regard, we have
previously reported the partial control of non-neutralizing gp41
MPER antibodies by tolerance controls [17], and others have
demonstrated that combinations of TLR agonists including
oCpGs and R848 have broken peripheral tolerance and induced
autoreactive antibodies [47,48,49,50]. Thus, strong adjuvants and
Figure 8. The JRFL gp140CF primed and MPER656 liposomes boosted rhesus macaque serum IgG bind scaffold proteins containing
engrafted MPER in the 2F5 bound conformation. A–C: SPR sensogram of 2F5, 11F10 and 13H11 mAbs at the indicated concentrations binding
to ES2 (A), ES4 (B), and ES5 (C) scaffolds respectively are shown. D–F: The post MPER656 liposome immune serum IgG of rhesus macaques (150 mg/
ml) binding to ES2 (D), EJ(E), ES5 (F) are shown. For the sake of clarity, the scaffold binding responses of pre-MPER656 liposome serum IgG of only
one animal (# 41546) is shown. The responses from other animal serum IgG were similar. Data is representative of at least two measurements.
doi:10.1371/journal.pone.0027824.g008
Table 1. Neutralization data of sera from JRFL gp140CF-
MPER656 liposomes immunized rhesus macaques.






2F5 mAb 2.4 mg/ml 3.6 mg/ml
Sera from immunized guinea pigs did not neutralize (data not shown).
doi:10.1371/journal.pone.0027824.t001
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immunogenicity of the 2F5 epitope of the MPER, but strategies for
the induction of the polyreactive antibodies needed for neutral-
izing activity have to be developed. In this regard, Matyas et al
have shown that liposomes containing the MPER and lipid A
induced polyreactive IgM but not IgG antibodies that simulta-
neously bind gp41 and phosphatidylinositol-4-phosphate and
neutralized HIV-1 in a peripheral blood mononuclear cells
neutralization assay [51].
That the prime boost regimen reported here and constrained
scaffolds can induce 2F5 core
664DKW epitope raises the question
of the utility of immunization with a gp41-inter protein constructs.
The prototype gp41 intermediate construct also contained the
post-fusion 6 helix bundle [14,32], and immune serum from
guinea pigs immunized with this construct did not focus antibodies
on
664DKW residues (Alam, M, Chen, B. et al. unpublished data).
Studies are underway with a GCN4 stabilized gp41 pre-hairpin
intermediate construct that does not contain the post-fusion six-
helix bundle.
Finally, these results indicate that mounting of responses to 2F5
core epitope as it exists in the fusion intermediate conformation of
gp41-inter alone is insufficient for HIV-1 neutralization. We have
previously shown that mutation in the 2F5 CDR H3 that abrogate
2F5 binding to lipids but maintain binding to the pre-hairpin gp41
intermediate conformation are unable to neutralize HIV-1 (2).
Thus, it is likely that the induced DKW-specific antibodies
described in this study also lack a hydrophobic CDR H3 loop that
renders them incapable of reacting with viral membrane lipids and
are thus unable to neutralize. This is consistent with the results
that 2F5 CDR H3 mutations greatly reduced the binding of
recombinant 2F5 to MPER peptide liposomes (Figure S8-A).
11F10 mAb, which lacks a hydrophobic CDRH3 [27], also gave
weak binding to MPER peptide liposomes (Figure S8-B). We had
proposed that the lack of lipid binding of 2F5 CDR H3 mutants
would prevent them from pre-concentrating on the viral
membrane and such antibodies would fail to capture the transient
fusion intermediate state of gp41 or to neutralize. Thus, while
IgGs from immunized rhesus macaques showed some binding to
MPER peptide-liposomes (Figure S8 C–F), the lack of lipid
binding would prevent the rhesus IgGs to maintain a kinetic head
start required for HIV-1 neutralization.
Materials and Methods
Ethics Statement
The guinea pig studies were carried out following a protocol
(A334-09-11) approved by the Animal Use and Care Committee
of the Duke University IACUC, which ensures that all animals in
experimental research are used appropriately and are treated with
the highest standards of humane care. Colony bred Indian-origin
rhesus monkeys used in the immunization studies were housed and
maintained in an Association for Assessment and Accreditation of
Laboratory Animal Care-accredited institution in accordance with
the principles of the National Institute of Health. All studies were
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health in BIOQUAL (Rockville, MD). BIOQUAL is
fully accredited by AAALAC and through OLAW, Assurance
Number A-3086. The animal protocol used in this study was
approved by the BIOQUAL IACUC (#08-3449-71). All physical
procedures associated with this work were done under anesthesia
to minimize pain and distress in accordance with the recommen-
dations of the Weatherall report, ‘‘The use of non-human primates
in research’’. Teklad 5038 Primate Diet was provided once daily
by animal size and weight. The diet was supplemented with fresh
fruit and vegetables. Fresh water was given ad libitum.
Proteins, Peptides, mAbs, Phospholipids and Adjuvants
Recombinant JRFL gp140CF (C=gp1202gp41 cleavage site
deleted; F=fusion domain-deleted, Figure S6) was produced and
purified using methods described earlier [52]. MPER peptides
containing the 2F5 epitope (QQEKNEQELLELDKWASLWN)
or the epitopes of both 2F5 and 4E10 mAbs (NEQELLELDK-
WASLWNWFNITNWLWYIK) were synthesized with a C-
terminal hydrophobic membrane anchor tag (YKRWIILGLN-
KIVRMYS) and purified by reverse phase HPLC. The purity of
the custom made (CPC Scientific) MPER peptides were assessed
by HPLC to be greater than 95% and confirmed by mass
spectrometric analysis. The gp41 inter proteins (92UG gp41-inter
and GCN4-gp41 inter, Figure S7) having gp41 sequence of clade
A HIV-1 isolate 92UG037.8 were produced as described earlier




phate (DMPA), cholesterol (CH), monophosphoryl Lipid A (MPL-
A) and bovine heart cardiolipin were obtained from Avanti Polar
Lipids and were used without further purification. R848 was
purchased from Axxora LLC. The custom made oCpG with 59
TCGTCGTTGTCGTTTTGTCGTT 39 (used in guinea pigs
immunization) and 59-(P=S)TCGTCGTTTTTCGGTCGTT-
TT-39 (used in rhesus macaques immunization) sequences was
obtained from The Midland Certified Reagent Co. Emulsigen was
purchased from MVP Laboratories. 2F5, 4E10 mAbs were
obtained from Polymun and Synagis was obtained from
Medimmune. 13H11 mAb and Fabs of 2F5 and 13H11 were
produced as described earlier [28,52]. Recombinant gp41 MN
was obtained from Immunodiagnostics. The recombinant 2F5
mAb and the mutants were produced in 293T cells as described
earlier [29].
The epitope scaffold proteins ES2, ES4 and ES5 and the 11F10
mAb were made as described earlier [27]. For antibody
preparation, 250 mg of light chain plasmid DNA and 250 mgo f
heavy chain plasmid DNA, or for ES2 and ES4 scaffolds, 500 mg
plasmid DNA, were mixed with 1 ml of 293fectin (Invitrogen,
Carlsbad, CA) for 20 minutes before the DNA-293fectin complex
was added into 850 ml of FreeStyle 293F cells (1.4610
6 cells/ml)
in a 2-L shaking flask. The transfected cells were returned to
suspension incubation for 2 days, and then, the culture was fed
with 50 ml of protein expression enriched medium CellBoost-5
(HyClone, Logan, UT) and protein expression enhancer Sodium
Butyrate at final concentration of 2 mM (SIGMA, St. Louis, MO).
After 6 days post transfection, supernatants were harvested by
centrifugation, filtered through 0.22 mm filter. The 11F10
antibody was purified by running the supernatant over a protein
A column (Pierce Protein A Plus Agarose, Thermo, Rockford, IL),
followed by elution at low pH. Purified antibody was dialyzed
against PBS, analyzed SDS-PAGE and stored at 280uC. The ES2
and ES4 scaffolds were purified by running the supernatant over a
2F5 antibody affinity column, followed by elution at low pH.
Bacterial expression and subsequent purification of epitope
scaffold ES5 was performed as previously described [27]. Briefly,
purification from inclusion bodies was undertaken under dena-
turing conditions of 8 M urea, 20 mM Tris-Cl, pH 8.0, 1 mM
beta-mercaptoethanol or DTT, followed by nickel chelating
chromatography in binding buffer comprised of 8 M urea,
500 mM NaCl, Tris-Cl, pH 8.0, imidazole 10 mM. Washes and
elutions were undertaken in binding buffer supplemented with
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performed at 4uC by dilution (1:100) into refolding buffer
comprised of 50 mM Tris-Cl, pH 8.0, 250 mM NaCl, 500 mM
L-Arginine, 0.1 mM glutathione reduced, 0.01 mM glutathione
oxidized, 0.03% N-laurylsarcosine and 0.1 mM ZnCl2.
Construction of adjuvant-containing MPER liposomes
The procedure used to prepare MPER peptide liposomes earlier
[19] was employed to construct adjuvant containing MPER
liposomes. Briefly, chloroform stocks of POPC, POPE, DMPA
and CH were mixed in glass tubes at a molar ratio of
45:25:20:1.33 respectively. The MPER peptide stock (made in
chloroform-methanol 7:3 v/v) solution was added to this mixture
to give a final peptide to total lipid ratio of 1:420. Appropriate
volumes of stock solutions of adjuvants MPL-A (in chloroform) and
R848 (in methanol) needed to yield desired dose of adjuvants were
added to the above lipid mixture. The lipids-peptide-adjuvant
mixture was dried under the stream of nitrogen to remove all
visible traces of chloroform and methanol. Any residual amount of
chloroform and methanol was removed by placing the dried film
under vacuum for overnight. The dried film was hydrated by
adding appropriate volume of PBS buffer (pH 7.4) and incubating
at 37uC for 45 minutes. The hydrated mixture was then sonicated
in a bath sonicator (Misonix 3000) and extruded through 0.4 mm
and 0.2 mm polycarbonate membranes using either a mini-
extruder obtained from Avanti Polar Lipids or a Lipex model
thermo barrel (Northern Lipids) extruder that uses high pressure
nitrogen gas for extrusion. The extruded liposomes were quality
controlled by checking for the binding of 2F5 or both 2F5 and
4E10 depending on the sequence of the MPER peptide as
described earlier [19]. The functionally active nature of liposome
incorporated MPL-A and R848 was confirmed by the ability of
MPER-adjuvant liposomal constructs to induce cytokine release in
human PBMC.
Immunizations
Guinea pigs were purchased from Charles River and housed in
the Vivarium at the Duke Human Vaccine Institute Animal
Research Facility. Some initial studies in guinea pigs (Figure 1B,
2B and 2E) involved immunization through intramuscular,
intranasal and sublingual routes with total dose of 100 mgo f
immunogen distributed in a 16:8:1 ratio respectively. In all other
studies, guinea pigs (4 animals per immunogen group) were
immunized every three weeks intramuscularly. At each immuni-
zation, the JRFL gp140CF group of guinea pigs were administered
intramuscularly with 400 ml (in two sites 200 ml/site) of recombi-
nant JRFL gp140CF formulated in 15% emulsigen and oCpG to
give a dose of 100 mg per animal of recombinant JRFL gp140 and
50 mg per animal of oCpG. The MPER liposome group of guinea
pigs received MPER/MPL-A liposomes formulated in 15%
emulsigen and oCpG. The MPER/MPL-A liposome immuniza-
tion involved intramuscular administration of guinea pigs at two
sites (200 ml per site). Each animal received a dose of 100 mg
MPER peptide, 200 mg of MPL-A and 50 mg of oCpG
respectively. Serum samples were collected 10 days after each
immunization and stored at 280uC until use.
Two groups of rhesus macaques were immunized intramuscu-
larly; one with JRFL gp140CF (100 mg per animal) adjuvanted
with AS01B (GSK Bio) and the second with MPER liposomes
(1 mg MPER peptide per animal) formulated in emulsigen and
oCPG (1 mg per animal) at weeks 0, 4, 8, 12 and 16. The ASO1B
adjuvant is a GSK-liposome adjuvant system containing MPL-A
and QS21. Serum samples were collected at weeks 2, 6, 10, 14 and
18. The JRFL gp140CF immunized rhesus macaques were
boosted with MPER/MPL-A/R848 liposomes (1 mg each of
MPER peptide, MPL-A and R848 per animal) at weeks 48, 51 and
55. Serum samples were collected at weeks 48, 49, 50, 51, 55 and
56 and were stored at 280uC until use.
Surface Plasmon Resonance assays for screening of
serum samples for MPER specific binding and epitope
mapping
The MPER specific binding responses present in immunized
animal serum samples were measured using a BIAcore 3000
instrument and data analyses were performed with BIAevaluation
4.1 software (Biacore). Biotinylated 2F5 nominal epitope peptide
(Biotin-SP62, QQEKNEQELLELDKWASLWN), 4E10 nominal
epitope peptide (Biotin-4E10p, SLWNWFNITNWLWYIK) and a
bi-epitope MPER peptide (Biotin-MPER656, NEQELLELDK-
WASLWNWFNITNWLW) were immobilized (150 RU) on
difference flow channels of a Streptavidin chip (Biacore). The
activity of immobilized MPER peptides was confirmed by
checking the binding of 2F5 or 4E10 mAbs at 5 or 10 mg/ml
concentration. The serum samples after 50 fold dilution in PBS
buffer (pH 7.4) were injected over the MPER peptide surfaces for
5 minutes at a 30 ml/minute flow rate. The responses were
continued to be monitored for 5 minutes after the injection of
diluted serum samples. The peptide surfaces were regenerated by
flowing over Glycine-HCl pH 2.0. A biotinylated scrambled
MPER peptide (NKEQDQAEESLQLWEKLNWL) immobilized
on the remaining flow channel served as a negative control surface
to subtract out the non-specific interactions of serum sample with
the chip. The dissociation phase of the MPER peptide specific
binding of sera was biphasic and could be resolved into a faster
and slower component. The dissociation rates shown in the figures
were derived from the initial faster phase. The gp41 inter proteins
(92UG gp41-inter and GCN4-gp41 inter) specific binding
responses in rhesus macaques sera were measured by flowing 50
fold diluted rhesus macaques sera over a CM5 chip immobilized
with ,500 RU of recombinant HIV-1 gp41 MN, gp41-inter
proteins and HIV-1 p66 protein surfaces. The binding responses
on HIV-1 p66 protein surface were used to subtract out responses
due to non-specific interactions. The IgGs purified from rhesus
macaques sera using Protein G spin columns and desalting
columns (Thermo Scientific) following manufacturer’s recom-
mended protocol were flowed at a 100 mg/ml concentration over
the gp41-inter proteins surfaces. The rhesus macaque serum IgGs
(150 mg/ml) binding to 2F5 epitope scaffolds was performed using
a CM5 chip immobilized with ,1500 RU of ES proteins.
Epitope mapping of MPER specific responses found in
immunized animal sera was carried out using a BIAcore A100
instrument and Streptavidin chip (Biacore). The biotinylated 2F5
nominal epitope peptide (Biotin-SP62) and seven of the biotiny-
lated alanine scanning mutant MPER peptides were immobilized
in duplicate on 16 different spots on four flow channels of the chip.
The median spot on each flow channel served as a blank surface to
subtract out non-specific interactions. The 50 fold diluted serum
samples were injected over the native and mutant MPER peptide
and reference surfaces for 5 minutes at a 30 ml/minute flow rate.
The dissociation phase was monitored for 10 minutes and the
surfaces were regenerated using Glycine-HCl pH 2.0 between
cycles. The responses at the end of the dissociation phase (450–
500 seconds after the injection of serum samples was over) were
averaged and used to calculate normalized binding response which
is defined as the ratio between the average binding response to a
mutant peptide and the corresponding binding response to the
native peptide.
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from rhesus macaques sera were performed using POPC-
Cardiolipin (25:75) liposomes and Biacore L1 chip as described
earlier [53].
ELISA assays for MPER binding
Direct binding ELISAs were conducted in 96 well ELISA
plates coated with 0.2 mg/well antigen (WT 2F5 epitope
peptide SP62) in 0.1 M sodium bicarbonate and blocked with
assay diluent (PBS containing 4% (w/v) whey protein/15%
Normal Goat Serum/0.5% Tween20/0.05% Sodium Azide).
Sera were incubated for 1 hour in two fold serial dilutions
beginning at 1:25 followed by washing with PBS/0.1% Tween-
20. 100 ml Alkaline phosphatase conjugated goat anti-human
secondary antibody was incubated for 1 hour, washed and
detected with 100 ml substrate (Carbonate-BiCarbonate (CBC)
buffer+2m M M g C l 2+1m g / m l p - n p p [ 4 - N i trophenyl phos-
phate di(2-amino-2-ethyl-1,3-propanediol) salt]). Plates were
read at 405 nm, 45 minutes.
Neutralization assay
The neutralizing activity of immune sera was determined by
monitoring reductions in luciferase (Luc) reporter-gene expression
after a single round of infection by pseudotyped HIV-1 viruses in
TZM-bl cells, as described previously [52].
Supporting Information
Figure S1 JRFL gp140CF specific responses mounted by
rhesus macaques immunized with JRFL gp140CF. ELISA
endpoint titer of immunized rhesus macaques sera showing
binding to JRFL gp140CF protein at different time points.
(TIF)
Figure S2 JRFL gp140 immunized rhesus macaques
mount gp41 specific responses that target a post-fusion
conformation of gp41. A–D: SPR sensogram of rhesus
macaques serum IgG (100 mg/ml) binding to recombinant gp41
MN (broken lines), gp41-inter (solid lines) and GCN4-gp41 inter
(dotted lines) and (broken lines). The IgGs purified from Week 14
sera of rhesus macaques were used.
(TIF)
Figure S3 11F10 mAb interaction with gp41-inter and
recombinant gp41 proteins. SPR sensogram of binding of
11F10 mAb at 2 (red), 5 (blue), 10 (green) and 20 (gray) mg/ml
concentration to (A) GCN4-gp41 inter, (B) 92UG gp41-inter and
(C) recombinant gp41 MN immobilized on a Biacore CM5 chip is
shown. The binding curves were fitted globally to a 1:1 Langmuir
model to obtain the displayed rate constants and dissociation
constant. The best fit are overlaid in black.
(TIF)
Figure S4 Binding of 11F10 mAb to anionic phospholip-
ids. A comparison of 11F10 (red), 2F5 (green) and 13H11 (blue)
mAbs binding responses to (A) phospatidylserine and (B)
cardiolipin containing liposomes is shown. The mAbs at
100 mg/ml concentration were flowed over POPC-POPS (25:75)
and POPC-Cardioipin (25:75) liposomes captured on a Biacore L1
chip.
(TIF)
Figure S5 Phospholipid binding of rhesus macaques
serum IgG. A: SPR sensogram of rhesus macaque (# 41546)
serum IgG (100 mg/ml) from week 0 (pre-bleed), 48 (pre-liposome
boost bleed) and 52 (post-liposome boost bleed) binding to
cardiolipin containing liposomes (POPC:cardiolipin 25:75) are
shown. The binding responses of 2F5 and 13H11 mAbs are shown
as comparison. B: The cardiolipin binding responses obtained for
all rhesus macaques serum IgG pre and post vaccination are
shown and compared with the binding responses of 2F5 and
13H11 mAbs. The binding responses of post vaccination IgG
(weeks 48–56) shown are week 0 bleeds response subtracted.
(TIF)
Figure S6 Schematics of protein and peptide constructs.
A: The JRFL gp140CF construct had the cleavage site, fusion
domain, transmembrane (TM) and cytoplasmic domains deleted
from the full length precursor gp160 sequence. The three residues
at the C-terminal are indicated. The construct was made using
methods reported earlier (Liao et al 2006). Blue-native PAGE
displayed on the right indicates the oligomeric nature of JRFL
gp140CF. B: A pictorial representation of MPER peptide-
liposome is shown. The liposomes were made using protocols
described earlier (Dennison et al 2009). C: The MPER sequence
of JRFL gp140CF is aligned with the sequence of MPER peptide
in the MPER656 liposome construct. The differences are coded in
red.
(TIF)
Figure S7 Schematic of gp41 fusion intermediate pro-
tein constructs. The design and trimer organization of gp41
inter proteins constructs used here to test the gp41 conformations
targeted by rhesus macaque IgGs is shown for (A) gp41- inter that
contains a six-helix bundle at the N-terminal and (B) GCN4-gp41
inter that has a trimeric GCN4 coiled coil and were described in
detail earlier (Frey et al 2008 and Frey et al 2010). HR2, heptad
repeat 2; HR1, heptad repeat 1; C-C loop, immunodominant
region with a disulfide bond; MPER, membrane proximal exernal
region; fd, trimerization fold on tag.
(TIF)
Figure S8 MPER peptide-liposome binding of mAbs and
rhesus macaques serum IgG. A: Mutation of hydrophobic
residues in CDR H3 loop of recombinant 2F5 mAb (L100aA,
F100bA and L100aA/F100bA) impedes binding to MPER
peptide-liposomes. The R95A mutation at the base of the CDR
H3 loop that was designed and demonstrated to disrupt gp41
binding (Alam et al 2009) showed no binding to MPER peptide-
liposomes. B: A comparison of the binding of MPER mabs 2F5,
11F10 and 13H11 to MPER peptide-liposomes is shown. C–F:
Rhesus macaques serum IgG of animals 03525 (C), 41546 (D),
51834 (E) and 51902 (F) to MPER peptide-liposomes are shown
for pre-immune (week 0) and post-MPER656 liposomes boost
bleeds. The sensograms shown were obtained by flowing mAbs
and serum IgGs at a 100 mg/ml concentration over MPER
liposomes (,500 RU) captured on a Biacore L1 chip. The non-
specific binding responses to the peptide-free liposomes
captured on a parallel flow cell in the same L1 chip were
subtracted to obtain specific b i n d i n gr e s p o n s e ss h o w ni nt h e
panels A through F.
(TIF)
Figure S9 The gp41 MPER specific antibody responses
in guinea pigs following double prime-boost immuniza-
tion. A: Scheme showing the prime-boost immunization strategy.
For the sake of clarity the time-line of immunization and blood-
draw is not shown. MPER liposomes containing 2F5 nominal
epitope peptide were used in immunizations 1 through 4 and 6
through 8. For immunizations 10 and 11 a longer MPER peptide
(MPER656) liposomes containing both 2F5 and 4E10 epitopes
were the preferred immunogen. Both MPER liposomes contained
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the 2F5 epitope peptide (SP62 peptide) specific responses in guinea
pigs sera from different bleeds. C: The 2F5 epitope peptide (SP62
peptide) specific responses of guinea pigs sera determined by SPR
are shown as a function of post-bleed number. P1-P11, post-
immune bleeds 1-11. D: SPR sensogram displaying the compar-
ison of 2F5 epitope peptide (SP62 peptide) specific binding of
guinea pig 1375 sera from different bleeds with 10mg/ml 2F5 mAb
is shown as representative data. E: Epitope mapping of post-
immune bleed 6-11 of guinea pig 1375 is shown in comparison to
2F5 mAb. The normalized binding shown is the ratio between
binding responses of sera to the alanine scanning mutant peptides
and WT 2F5 epitope peptide SP62. The dotted circle highlights
the mapping of MPER specific responses in guinea pig 1375 sera
to D
664KW
666 residues as did 2F5 mAb. Data is representative of
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